EN DE
Watch QuantaMatrix Inc. for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

QuantaMatrix Inc. (317690) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of QuantaMatrix Inc. stock ₩1,302, price ₩1,561, that is 16.6% below the price, quality 36 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

QI QuantaMatrix Inc. logo Thin data Nov 16, 2026

QuantaMatrix Inc.

317690 · KQ

Expensive (fair value 17% below the price), weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Expensive Growth (revenue 5y +16.9 %/yr in KRW) 
Revenue last quarter 28% below a year ago. 
Fair value ₩1,302 · Overvalued 
Quality 36/100 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (1/8) 
Narrow moat 9/100 · thin data
Thin data 
Estimate
Watch QuantaMatrix Inc. for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₩22,000 ₩1,561 Fair Value ₩1,302 Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range ₩1,561 – ₩22,000 · fair‑value band ₩976 – ₩1,627 · the ₩1,561 price screens above the ₩1,302 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow QuantaMatrix in your weekly email

Every Wednesday you see whether QuantaMatrix is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea.

Show moreShow less

Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases.

QuantaMatrix Inc. was founded in 2010 and is based in Seoul, South Korea.

Stock analysis

QuantaMatrix Inc. (317690) currently trades at ₩1,561, while our estimate is ₩1,302, 17% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ₩976 (bear) to ₩1,627 (bull), the price of ₩1,561 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

QuantaMatrix Inc. reported revenue of 3.7B KRW in FY2025 versus 550M KRW in FY2021, a compound +60.9%/yr. Reported net income was −19.5B KRW in FY2025.

Key figures

Market cap 31.4B KRW (≈ $23.5M) Micro · P/S ratio 12.9 · EPS (TTM) ₩-886 · Return on equity −96.9% · Return on assets (EBIT) −52.3% (5-year average) · Operating margin −653% · Revenue (TTM) 3.1B KRW · Revenue growth (quarter YoY) −28.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).

What moves the price

The share trades about 70% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −17%, 317690 screens richer than that median.

Fair Value

Bear ₩976 Fair Value ₩1,302 Bull ₩1,627
Price ₩1,561 · Downside -16.6%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 88
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 67
Debt, balance sheet and risk of trouble
Investment 61
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 2
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 10
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+47.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.9%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+72.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−878.0% (2020) → −422.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

317690 screens overvalued: fair value 17% below the price. Compare with Abbott Laboratories, →

Compare QuantaMatrix Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 399 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside −16.6% · Below median
Profitability
Return on assets −37.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −28.0% · Bottom 25%
Balance sheet
Debt / equity 0.39× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.79× · Cheapest 25%
P/S (12 months) 9.99× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)11 · sector 19
FUTURE (revenue growth)0 · sector 41
PAST (return on equity)0 · sector 2
HEALTH (low debt)81 · sector 97
DIVIDEND (yield)0 · sector 35

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

QuantaMatrix Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "QuantaMatrix Inc. Fair Value". https://www.fairvalue-calculator.com/stock/317690

Frequently asked questions

Is QuantaMatrix Inc. (317690) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is ₩1,302 versus a price of ₩1,561, about 17% lower (overvalued).
What is the fair value of 317690?
Our estimate for QuantaMatrix Inc. is ₩1,302 (as of Nov 16, 2026), built from audited fundamentals. The current price: ₩1,561.
What is the quality score of 317690?
QuantaMatrix Inc. has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for QuantaMatrix Inc. (317690)?
We do not set a price target; the yardstick is our estimate of ₩1,302 (as of Nov 16, 2026). Cautious scenario ₩976, optimistic scenario ₩1,627. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the QuantaMatrix Inc. stock forecast for 2026?
Our estimate puts fair value at ₩1,302, about 17% lower versus a price of ₩1,561 (overvalued). Cautious scenario ₩976, optimistic scenario ₩1,627. The calculation is refreshed regularly with new filings.
What is the revenue of QuantaMatrix Inc. (317690)?
QuantaMatrix Inc. reported trailing-twelve-month revenue of about 3.1B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of QuantaMatrix Inc. (317690)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For QuantaMatrix Inc. it is ₩1,302 per share (as of Nov 16, 2026), against a price of ₩1,561.
Is QuantaMatrix Inc. stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 317690 trades above its calculated fair value: price ₩1,561, fair value ₩1,302, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 317690?
No. The price is what the market pays today (₩1,561); the fair value is what the company's own numbers justify (₩1,302). For QuantaMatrix Inc. the two are ₩259 per share apart. That gap is exactly why we show both numbers side by side.
How much is QuantaMatrix Inc. worth?
The market values QuantaMatrix Inc. at about 31.4B KRW (market capitalisation, as of Nov 16, 2026). Per share that is ₩1,561; our models calculate a fair value of ₩1,302 per share.
What do the bullish and bearish scenarios say about 317690?
Our models span a range for QuantaMatrix Inc.: cautious scenario ₩976, base ₩1,302, optimistic ₩1,627 per share (as of Nov 16, 2026, price ₩1,561). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of QuantaMatrix Inc. (317690)?
Balance-sheet figures for QuantaMatrix Inc. (as of Nov 16, 2026): return on equity −96.9%, debt of 0.39 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is 317690 from its 52-week high?
QuantaMatrix Inc. trades at ₩1,561, about 70% below its 52-week high of ₩5,180 and at the low of ₩1,561 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of ₩1,302 is for.
Which stocks are comparable to QuantaMatrix Inc.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is QuantaMatrix Inc. stock attractive at the current price?
The data as of Nov 16, 2026: price ₩1,561, calculated fair value ₩1,302 (−17%), Quality Score 36/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. QuantaMatrix Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of QuantaMatrix Inc. (317690)?
The closing price on Nov 20, 2026 was ₩1,561. Our estimate is ₩1,302, about 17% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with QuantaMatrix Inc. right now?
Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of QuantaMatrix Inc.

How large is the market capitalisation of QuantaMatrix Inc. (317690)?
The market capitalisation of QuantaMatrix Inc. is 31.4B KRW (≈ $23.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of QuantaMatrix Inc. (317690)?
The price-to-sales ratio of QuantaMatrix Inc. is 12.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of QuantaMatrix Inc. (317690)?
Earnings per share at QuantaMatrix Inc. are ₩-886. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of QuantaMatrix Inc. (317690)?
The return on equity (ROE) of QuantaMatrix Inc. is −96.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of QuantaMatrix Inc. (317690)?
On an EBIT basis the return on assets of QuantaMatrix Inc. is −52.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of QuantaMatrix Inc. (317690)?
The operating margin of QuantaMatrix Inc. is −653% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at QuantaMatrix Inc. (317690)?
Revenue at QuantaMatrix Inc. is down 28.0% in the last quarter versus the same quarter a year earlier (3y avg +42.1%). How much revenue grew in the last quarter versus the same quarter a year earlier (YoY). The 3-year average next to it puts the single quarter in context.
How much free cash flow does QuantaMatrix Inc. (317690) generate?
The free cash flow of QuantaMatrix Inc. is −15.7B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does QuantaMatrix Inc. (317690) carry?
The net debt of QuantaMatrix Inc. is 9.3B KRW (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch QuantaMatrix Inc. in the live analysis

One click puts QuantaMatrix Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.